Zika Envelope N

Zika Envelope N-Terminal Recombinant
Cat. No.
BT11130
Source
Escherichia Coli.
Synonyms
Appearance
Sterile Filtered solution.
Purity

Zika Envelope N protein is >95% pure as determined by SDS-PAGE.

Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock
Quick Inquiry

Description

Zika Envelope N protein is a peptide partially derived from zika envelope N terminal containing 270 amino acids, having an Mw of 30kDa and the Isoelectric point is 6.37.
The Zika Envelope N protein is fused to a 6xHis tag at C-terminus and purified by proprietary chromatographic technique.

Product Specs

Introduction
The Zika virus (ZIKV) is a member of the Flaviviridae family and the Flavivirus genus. Transmitted primarily through the bite of infected Aedes mosquitoes, particularly Aedes aegypti and Aedes albopictus, ZIKV is closely related to other flaviviruses such as dengue, yellow fever, Japanese encephalitis, and West Nile viruses. Similar to its viral relatives, ZIKV possesses an enveloped, icosahedral structure containing a nonsegmented, single-stranded RNA genome of positive polarity. Infection with ZIKV typically results in Zika fever, a disease often characterized by mild or absent symptoms resembling a mild form of dengue fever. Rest is generally recommended as the primary treatment for Zika fever. However, concerns have been raised regarding the potential link between ZIKV infection during pregnancy and adverse fetal outcomes. Mounting evidence suggests that ZIKV can be transmitted from mother to fetus, potentially leading to congenital abnormalities such as microcephaly and miscarriage. While the exact nature of the association between ZIKV and microcephaly remains to be fully elucidated, the potential implications for fetal development are significant. Moreover, recent studies have established a connection between ZIKV infection in adults and neurological complications, including Guillain-Barré syndrome. Historically, ZIKV was primarily confined to a narrow equatorial region spanning Africa and Asia. However, between 2013 and 2014, the virus embarked on an eastward expansion across the Pacific Ocean, reaching French Polynesia, New Caledonia, the Cook Islands, and Easter Island. This geographical expansion continued in 2015, with ZIKV reaching the shores of Mexico, Central America, the Caribbean, and South America, culminating in a widespread Zika outbreak that reached pandemic proportions.
Description
The Zika Envelope N protein is a peptide fragment derived from the N-terminal region of the Zika virus envelope protein. This 270-amino acid peptide has a molecular weight of 30 kDa and an isoelectric point of 6.37. To facilitate purification and detection, a 6xHis tag has been fused to the C-terminus of the Zika Envelope N protein. The protein is purified using a proprietary chromatographic technique, ensuring a high degree of purity.
Physical Appearance
Clear, sterile-filtered solution.
Formulation
The Zika Envelope N protein solution is supplied in phosphate-buffered saline (PBS) containing 0.05% sodium azide (NaN3) as a preservative.
Stability
For short-term storage (up to 1 week), the Zika Envelope N protein solution can be stored at 4°C. However, for long-term storage, it is recommended to store the protein solution at -18°C or below. Repeated freeze-thaw cycles should be avoided to maintain protein integrity and activity.
Purity
Analysis by SDS-PAGE reveals that the Zika Envelope N protein is greater than 95% pure, indicating a high level of purity.
Applications
The optimal working concentration of the Zika Envelope N protein may vary depending on the specific application and experimental conditions. Therefore, it is recommended that each laboratory empirically determine the most suitable working titer for their intended use.
Source
Escherichia Coli.

Product Science Overview

Introduction

The Zika virus (ZIKV) is an arthropod-borne virus belonging to the family Flaviviridae and the genus Flavivirus. It was first identified in a rhesus monkey in the Zika forest of Uganda in 1947 . ZIKV is known for causing neurological abnormalities and has become a significant global health concern, necessitating the development of accurate diagnostics, effective vaccines, and therapeutics .

Zika Virus Envelope Protein

The envelope (Env) protein of ZIKV plays a crucial role in the virus’s life cycle. It is involved in receptor binding, fusion, and viral entry into target cells. The Env protein is also a primary target for neutralizing antibodies during ZIKV infection . The Env protein is composed of three domains: DI, DII, and DIII, with DIII being particularly important for eliciting neutralizing antibodies .

Recombinant Zika Envelope N-Terminal Protein

The N-terminal 80% of the ZIKV envelope protein (80E) has been expressed recombinantly in various systems, including Pichia pastoris and mammalian cells . This recombinant protein has been studied for its potential use in vaccines and diagnostic assays.

Expression in Pichia pastoris

In one study, the N-terminal 80% of the ZIKV envelope protein was expressed in the yeast Pichia pastoris. The recombinant protein self-assembled into particulate structures, preserving the antigenic integrity of neutralizing epitopes on the E domain III (EDIII). This recombinant protein elicited potent ZIKV-neutralizing antibodies predominantly against EDIII in BALB/c mice, offering significant protection without the risk of antibody-dependent enhancement (ADE) upon subsequent dengue virus (DENV) or ZIKV infection .

Expression in Mammalian Cells

Another study focused on optimizing the production of the ZIKV envelope protein in mammalian cells. Various gene expression constructs were designed to produce the ZIKV envelope protein with or without a rat CD4 fusion partner. The resulting Env-CD4 protein was used as a coating reagent for immunoassays (ELISA) and demonstrated the ability to bind antibodies from ZIKV-infected patient sera. This recombinant protein showed potential for use in monitoring humoral immune responses in clinical trials and as a sero-diagnostic tool in ZIKV infection .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

Related Products

Zika Envelope Antibody
Polyclonal Rabbit Anti Zika envelope
Cat. No.
BT5072
Source
Zika Ectodomain
Zika Ectodomain Recombinant
Cat. No.
BT10790
Source
Baculovirus Insect Cells.
Zika Envelope
Zika Envelope Recombinant
Cat. No.
BT10824
Source
Escherichia Coli.
Zika Envelope Domain-3
Zika Envelope Domain-III Recombinant
Cat. No.
BT10939
Source
Escherichia Coli.
THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.